| Bioactivity | Apstatin is a potent aminopeptidase P (APP) inhibitor with Ki values of 2.6, 0.64 µM for rat and human APP, respectively. Apstatin shows cardioprotection[1][2]. |
| Target | IC50: 2.6 µM (rat APP); 0.64 µM (human APP) |
| In Vivo | Apstatin (1 mg/kg; i.v.; 5 min before ischaemia) 可减少急性心肌缺血模型中的心肌梗塞面积 (IS)[1]。 MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: |
| CAS | 160470-73-5 |
| Formula | C23H33N5O5 |
| Molar Mass | 459.54 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Wolfrum S, et al. Apstatin, a selective inhibitor of aminopeptidase P, reduces myocardial infarct size by a kinin-dependent pathway. Br J Pharmacol. 2001 Sep;134(2):370-4. [2]. Maggiora LL, et al. Apstatin analogue inhibitors of aminopeptidase P, a bradykinin-degrading enzyme. J Med Chem. 1999 Jul 1;42(13):2394-402. |